Skip to main content

How artificial intelligence can help detect rare diseases

Every year, around half a million children worldwide are born with a rare hereditary disease. Obtaining a definitive diagnosis can be difficult and time consuming. In a study of 679 patients with 105 different rare diseases, scientists from the University of Bonn and the Charité -- Universitätsmedizin Berlin have shown that artificial intelligence can be used to diagnose rare diseases more efficiently and reliably. A neural network automatically combines portrait photos with genetic and patient data. The results are now presented in the journal Genetics in Medicine.
Many patients with rare diseases go through lengthy trials and tribulations until they are correctly diagnosed. "This results in a loss of valuable time that is actually needed for early therapy in order to avert progressive damage," explains Prof. Dr. med. Dipl. Phys. Peter Krawitz from the Institute for Genomic Statistics and Bioinformatics at the University Hospital Bonn (UKB). Together with an international team of researchers, he demonstrates how artificial intelligence can be used to make comparatively quick and reliable diagnoses in facial analysis.
The researchers used data of 679 patients with 105 different diseases caused by the change in a single gene. These include, for example, mucopolysaccharidosis (MPS), which leads to bone deformation, learning difficulties and stunted growth. Mabry syndrome also results in intellectual disability. All these diseases have in common that the facial features of those affected show abnormalities. This is particularly characteristic, for example, of Kabuki syndrome, which is reminiscent of the make-up of a traditional Japanese form of theatre. The eyebrows are arched, the eye-distance is wide and the spaces between the eyelids are long.
The used software can automatically detect these characteristic features from a photo. Together with the clinical symptoms of the patients and genetic data, it is possible to calculate with high accuracy which disease is most likely to be involved. The AI and digital health company FDNA has developed the neural network DeepGestalt, which the researchers use as a tool of artificial intelligence for their study. "PEDIA is a unique example of next-generation phenotyping technologies," said Dekel Gelbman, CEO of FDNA. "Integrating an advanced AI and facial analysis framework such as DeepGestalt into the variant analysis workflow will result in a new paradigm for superior genetic testing."
Researchers train the neural network with 30,000 images
The scientists trained this computer program with around 30,000 portrait pictures of people affected by rare syndromal diseases. "In combination with facial analysis, it is possible to filter out the decisive genetic factors and prioritize genes," says Krawitz. "Merging data in the neuronal network reduces data analysis time and leads to a higher rate of diagnosis."
The head of the Institute of Genomic Statistics and Bioinformatics at the UKB has been working with FDNA for some time. "This is of great scientific interest to us and also enables us to find a cause in some unsolved cases," said Krawitz. Many patients are currently still looking for an explanation for their symptoms.
The study is a team effort between computer science and medicine. This can also be seen in the shared first authorship of the computer scientist Tzung-Chien Hsieh, doctoral student at the institute of Professor Krawitz, and Dr. Martin Atta Mensah, physician at the Institute of Medical Genetics and Human Genetics of the Charité and Fellow of the Clinician Scientist Program of the Charité and Berlin Institute of Health (BIH). Prof. Dr. Stefan Mundlos, Director of the Institute of Medical Genetics and Human Genetics at the Charité, also participated in the study, as did over 90 other scientists.
"Patients want a prompt and accurate diagnosis. Artificial intelligence supports physicians and scientists in shortening the journey," says Dr. Christine Mundlos, Deputy Managing Director of the alliance of patients with chronic rare diseases (ACHSE) e.V. "This also improves the quality of life of those affected to some extent."
Story Source:
Materials provided by University of Bonn.
 Note: Content may be edited.

Comments

Post a Comment

Popular posts from this blog

Size matters: New data reveals cell size sparks genome awakening in embryos

Transitions are a hallmark of life. When dormant plants flower in the spring or when a young adult strikes out on their own, there is a shift in control. Similarly, there is a transition during early development when an embryo undergoes biochemical changes, switching from being controlled by maternal molecules to being governed by its own genome. For the first time, a team from the Perelman School of Medicine at the University of Pennsylvania found in an embryo that activation of its genome does not happen all at once, instead it follows a specific pattern controlled primarily by the various sizes of its cells. The researchers published their results this week as the cover story in  Developmental Cell . In an early embryo undergoing cell division, maternally loaded RNA and proteins regulate the cell cycle. The genomes of the zygote -- a term for the fertilized egg -- are initially in sleep mode. However, at a point in the early life of the embryo, these zygotic nuclei "wake...
Post a Comment
Read more

Home births as safe as hospital births: International study suggests

A large international study led by McMaster University shows that low risk pregnant women who intend to give birth at home have no increased chance of the baby's perinatal or neonatal death compared to other low risk women who intend to give birth in a hospital. The results have been published by  The Lancet 's  EClinicalMedicine  journal. "More women in well-resourced countries are choosing birth at home, but concerns have persisted about their safety," said Eileen Hutton, professor emeritus of obstetrics and gynecology at McMaster, founding director of the McMaster Midwifery Research Centre and first author of the paper. "This research clearly demonstrates the risk is no different when the birth is intended to be at home or in hospital." The study examined the safety of place of birth by reporting on the risk of death at the time of birth or within the first four weeks, and found no clinically important or statistically different risk between home...
Post a Comment
Read more

Molecular adlayer produced by dissolving water-insoluble nanographene in water

Molecular adlayer produced by dissolving water-insoluble nanographene in water : "Nanographene incorporated micelle capsules" can be prepared by simply pulverizing and mixing nanographene with amphiphilic V-shaped anthracene molecules in water at room temperature. Even though nanographene is insoluble in water and organic solvents, Kumamoto University (KU) and Tokyo Institute of Technology (Tokyo Tech) researchers have found a way to dissolve it in water. Using "molecular containers" that encapsulate water-insoluble molecules, the researchers developed a formation procedure for a nanographene adlayer, a layer that chemically interacts with the underlying substance, by just mixing the molecular containers and nanographene together in water. The method is expected to be useful for the fabrication and analysis of next-generation functional nanomaterials. Graphene is a single layer of carbon atoms arranged in sheet form. It is lighter than metal wit...
Post a Comment
Read more